Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin
To investigate the effect of medrogestone on bone mineral density (BMD) and bone turnover under conditions of estrogen withdrawal, premenopausal women with endometriosis were treated with goserelin (Zoladex®), combined with either placebo (group A, n = 12) or 10 mg medrogestone (Prothil®, group B, n...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1999
|
| In: |
Experimental and clinical endocrinology & diabetes
Year: 1999, Jahrgang: 107, Heft: 6, Pages: 379-385 |
| ISSN: | 1439-3646 |
| DOI: | 10.1055/s-0029-1212129 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1055/s-0029-1212129 Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0029-1212129 
|
| Verfasserangaben: | M. Sillem, M. Parviz, H.W. Woitge, L. Kiesel, U. Ulrich, Th. von Holst, B. Runnebaum, R. Ziegler, M.J. Seibel |
| Zusammenfassung: | To investigate the effect of medrogestone on bone mineral density (BMD) and bone turnover under conditions of estrogen withdrawal, premenopausal women with endometriosis were treated with goserelin (Zoladex®), combined with either placebo (group A, n = 12) or 10 mg medrogestone (Prothil®, group B, n = 11) for six months, and followed for an additional six months. Lumbar spine BMD was measured at 0 and 6 month. Markers of bone turnover were serum bone alkaline phosphatase (sBAP) and osteocalcin (sOC) by ELISA, and urinary total pyridinoline (uPYD) and deoxypyridinoline crosslinks (uDPD) by HPLC. |
|---|---|
| Beschreibung: | Elektronische Reproduktion der Print-Ausgabe, 14. Juli 2009 |
| Beschreibung: | Online Resource |
| ISSN: | 1439-3646 |
| DOI: | 10.1055/s-0029-1212129 |